纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | IL22R |
Uniprot No | Q8N6P7 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 250-573aa |
氨基酸序列 | SYRYVTKPPAPPNSLNVQRVLTFQPLRFIQEHVLIPVFDLSGPSSLAQPVQYSQIRVSGPREPAGAPQRHSLSEITYLGQPDISILQPSNVPPPQILSPLSYAPNAAPEVGPPSYAPQVTPEAQFPFYAPQAISKVQPSSYAPQATPDSWPPSYGVCMEGSGKDSPTGTLSSPKHLRPKGQLQKEPPAGSCMLGGLSLQEVTSLAMEESQEAKSLHQPLGICTDRTSDPNVLHSGEEGTPQYLKGQLPLLSSVQIEGHPMSLPLQPPSRPCSPSDQGPSPWGLLESLVCPKDEAKSPAPETSDLEQPTELDSLFRGLALTVQWE |
预测分子量 | 50.8kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-22受体(IL-22R)重组蛋白研究的代表性文献,按研究重点分类整理:
---
1. **文献名称**:*Crystal structure of recombinant human IL-22 bound to its high-affinity IL-22R1 subunit*
**作者**:Jones BC, et al.
**摘要**:通过X射线晶体学解析了重组人IL-22与IL-22R1胞外结构域的复合物三维结构,揭示了配体-受体结合的分子机制,为靶向药物设计提供结构基础。
2. **文献名称**:*IL-22R ligands IL-20 and IL-24 regulate wound healing in murine models*
**作者**:Sa SM, et al.
**摘要**:利用重组IL-22R蛋白阻断实验,证明IL-20/IL-24通过结合IL-22R1调控皮肤上皮细胞再生,提示IL-22R信号通路在组织修复中的关键作用。
3. **文献名称**:*Targeting IL-22RA1 with a recombinant antibody ameliorates intestinal inflammation in murine colitis*
**作者**:Xu W, et al.
**摘要**:开发靶向IL-22Rα1的重组单克隆抗体,在DSS诱导的结肠炎小鼠模型中有效抑制IL-22信号传导,缓解肠道炎症和屏障损伤。
---
**补充说明**:IL-22R相关研究多聚焦于其与自身免疫疾病(银屑病、IBD)和癌症的关联,重组蛋白技术常被用于解析受体功能或开发治疗性抗体。
Interleukin-22 receptor (IL-22R) is a heterodimeric protein complex composed of two subunits: IL-22R1 (IL-22RA1) and IL-10R2 (IL-10RB). It belongs to the class II cytokine receptor family and serves as the primary signaling receptor for interleukin-22 (IL-22), a member of the IL-10 cytokine family. IL-22 is predominantly produced by immune cells, including T helper 17 (Th17) cells, innate lymphoid cells (ILCs), and γδ T cells, and plays a critical role in modulating tissue responses at barrier surfaces, such as the skin, lungs, and gastrointestinal tract. The binding of IL-22 to IL-22R activates downstream signaling pathways, primarily the JAK-STAT (Janus kinase-signal transducer and activator of transcription) cascade, leading to STAT3 phosphorylation and the regulation of genes involved in cell survival, proliferation, and antimicrobial defense.
Recombinant IL-22R proteins are engineered versions of the receptor or its subunits, often produced in mammalian or insect cell systems to ensure proper post-translational modifications. These proteins are widely used in research to study IL-22 signaling mechanisms, receptor-ligand interactions, and the pathophysiological roles of IL-22 in diseases such as psoriasis, inflammatory bowel disease (IBD), and cancer. For example, soluble IL-22R1 ectodomain can act as a decoy receptor to neutralize IL-22 activity, providing insights into therapeutic strategies for IL-22-driven pathologies. Conversely, recombinant IL-22R complexes may also be employed to enhance IL-22 signaling in models of tissue repair or infection.
The development of IL-22R-targeted therapies remains an active area of investigation, particularly for conditions involving dysregulated epithelial immunity. However, the duality of IL-22’s roles—both protective and pro-inflammatory—requires careful modulation of its receptor interactions. Recombinant IL-22R proteins thus serve as essential tools for dissecting these complexities and advancing translational applications.
×